NCT05432934

Brief Summary

Dexamethasone will be used as an adjunct to local anesthetics (bupivacaine) to prolong the duration of laparoscopically-placed transversus-abdominis plane blocks in elective colorectal resection.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Sep 2022

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 28, 2021

Completed
9 months until next milestone

First Posted

Study publicly available on registry

June 27, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2024

Completed
Last Updated

December 7, 2023

Status Verified

November 1, 2023

Enrollment Period

1.6 years

First QC Date

September 28, 2021

Last Update Submit

November 30, 2023

Conditions

Keywords

perioperative analgesiaTAP blocklaparoscopic surgeryregional anesthesia

Outcome Measures

Primary Outcomes (1)

  • Total postoperative opioid consumption in the first 48 hours after surgery (hydromorphone equivalents.

    48 hours

Secondary Outcomes (3)

  • Opioid consumption in the post-anesthetic care unit (PACU)

    48 hours

  • Length of stay in post-anesthetic care unit (minutes).

    60-120 minutes

  • Length of stay in hospital (days).

    3-7 days

Study Arms (2)

Dexamethasone

EXPERIMENTAL

Dexamethasone 16mg will be added to local anesthetic solution for TAP blocks. 4mg will be injected at 4 anterior abdominal wall sites in a laparoscopically-administered TAP block. This is a single intraoperative dose.

Drug: Dexamethasone

Local anesthetic only

NO INTERVENTION

Local anesthetic (bupivacaine 0.25) 1mL/kg will be used for TAP blocks.

Interventions

Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.

Dexamethasone

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age \> 18
  • ASA class I-III
  • elective or urgent inpatient laparoscopic/laparoscopic assisted colorectal surgery.

You may not qualify if:

  • emergency surgery
  • open surgery
  • contraindications to laparoscopic surgery (ie. adhesions, inability to tolerate pneumoperitoneum)
  • ASA class 4
  • age \< 18
  • pregnant or breastfeeding women
  • significant cardiorespiratory/hepatic/renal disease
  • allergy to any study drugs
  • inability to consent
  • inability to respond to pain assessments
  • inability to use the patient-controlled analgesia device (PCA)
  • preoperative chronic opioid use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal University Hospital

Saskatoon, Saskatchewan, S7N 0W8, Canada

RECRUITING

MeSH Terms

Conditions

AgnosiaPain, PostoperativeColorectal NeoplasmsCrohn DiseaseDiverticular Diseases

Interventions

Dexamethasone

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsPostoperative ComplicationsPathologic ProcessesPainIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesInflammatory Bowel DiseasesGastroenteritis

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Officials

  • David N Ginther, MD

    University of Saskatchewan

    PRINCIPAL INVESTIGATOR

Central Study Contacts

David N Ginther, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

September 28, 2021

First Posted

June 27, 2022

Study Start

September 1, 2022

Primary Completion

March 31, 2024

Study Completion

August 31, 2024

Last Updated

December 7, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations